US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Braveheart Bio Inc. (BRVE): Fidelity Anchoring a Phase 3 Cardiac Biotech with Sector Momentum

Braveheart Bio Inc. (BRVE): Fidelity's Bet Pays Off as IPO Rockets Higher on Debut

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Phase 3-ready lead asset positions Braveheart among later-stage biotech IPOs, with BHB-1893 targeting obstructive and non-obstructive HCM.</li>
<li>Fidelity's proposed $75 million anchor investment and a blue-chip healthcare investor base provide meaningful validation ahead of the offering.</li>
<li>Clinical data suggest BHB-1893 may offer safety and dosing advantages over existing therapies, though pivotal Phase 3 studies remain the key catalyst.</li>
</ul>


Phase 3-ready lead asset positions Braveheart among later-stage biotech IPOs, with BHB-1893 targeting obstructive and non-obstructive HCM.
Fidelity's proposed $75 million anchor investment and a blue-chip healthcare investor base provide meaningful validation ahead of the offering.
Clinical data suggest BHB-1893 may offer safety and dosing advantages over existing therapies, though pivotal Phase 3 studies remain the key catalyst.


Braveheart Bio Inc. (BRVE): Phase 3 Hypertrophic Cardiomyopathy Biotech Sets Terms for IPO